Phase I dose-escalation study of oral administration of the selective Bcl2 inhibitor S55746 in patients with refractory or relapsed Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Servier 1 (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors IRIS
- 14 Mar 2018 Planned End Date changed from 8 Oct 2019 to 1 Sep 2018.
- 14 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Sep 2018.
- 14 Mar 2018 Status changed from recruiting to active, no longer recruiting.